Item Type | Name |
Concept
|
Prostate-Specific Antigen
|
Academic Article
|
The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study.
|
Academic Article
|
Genome-wide methylation analysis identifies involvement of TNF-a mediated cancer pathways in prostate cancer.
|
Academic Article
|
New therapies for castration-resistant prostate cancer: efficacy and safety.
|
Academic Article
|
New treatment options for castrate-resistant prostate cancer: a urology perspective.
|
Academic Article
|
An Internet intervention for management of uncertainty during active surveillance for prostate cancer.
|
Academic Article
|
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
|
Academic Article
|
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
|
Academic Article
|
Targeting angiogenesis as a promising modality for the treatment of prostate cancer.
|
Academic Article
|
Prostate cancer biomarker: a key field to explore.
|
Academic Article
|
Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray.
|
Academic Article
|
Quantifying the amount of variation in survival explained by prostate-specific antigen.
|
Academic Article
|
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
|
Academic Article
|
Novel trial designs: which agents and how do we test them?
|
Academic Article
|
Editorial: States and state transitions are all that really matter.
|
Academic Article
|
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
|
Academic Article
|
Bisphosphonates for men with prostate cancer: sifting through the rubble.
|
Academic Article
|
Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements.
|
Academic Article
|
Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
|
Academic Article
|
Use of nomograms for predicting survival in patients with castrate prostate cancer.
|
Academic Article
|
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
|
Academic Article
|
Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
|
Academic Article
|
Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
|
Academic Article
|
High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care?
|
Academic Article
|
Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference.
|
Academic Article
|
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
|
Academic Article
|
Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer.
|
Academic Article
|
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
|
Academic Article
|
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
|
Academic Article
|
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.
|
Academic Article
|
Epothilones in prostate cancer.
|
Academic Article
|
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
|
Academic Article
|
Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
|
Academic Article
|
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
|
Academic Article
|
The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
|
Academic Article
|
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
|
Academic Article
|
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer.
|
Academic Article
|
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
|
Academic Article
|
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
|
Academic Article
|
Exosomal avß6 integrin is required for monocyte M2 polarization in prostate cancer.
|
Academic Article
|
Prostate cancer sheds the avß3 integrin in vivo through exosomes.
|
Academic Article
|
Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
|
Academic Article
|
Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
|
Academic Article
|
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
|
Academic Article
|
Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
|
Academic Article
|
Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer.
|
Academic Article
|
Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.
|
Academic Article
|
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel.
|
Academic Article
|
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
|
Academic Article
|
Preserving Well-being in Patients With Advanced and Late Prostate Cancer.
|
Academic Article
|
Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer.
|
Academic Article
|
Differential expression of aVß3 and aVß6 integrins in prostate cancer progression.
|
Academic Article
|
Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs.
|
Academic Article
|
Overview of Prostate Cancer Genetic Testing.
|
Academic Article
|
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
|
Academic Article
|
Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation.
|
Academic Article
|
Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice.
|
Academic Article
|
Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.
|
Academic Article
|
A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration Resistant Prostate Cancer.
|
Academic Article
|
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
|
Academic Article
|
Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.
|
Academic Article
|
Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review.
|
Academic Article
|
The NOGO receptor NgR2, a novel aV?3 integrin effector, induces neuroendocrine differentiation in prostate cancer.
|
Academic Article
|
STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer.
|
Academic Article
|
A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer.
|
Academic Article
|
Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease.
|
Academic Article
|
Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer.
|
Academic Article
|
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer.
|
Academic Article
|
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Na?ve Metastatic Castration-Resistant Prostate Cancer.
|
Academic Article
|
Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer.
|
Academic Article
|
Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
|
Academic Article
|
Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer.
|
Academic Article
|
Xaluritamig, a STEAP1 ? CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
|
Academic Article
|
Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.
|
Academic Article
|
TARGETING THE?aV?3/NgR2 PATHWAY?IN NEUROENDOCRINE PROSTATE CANCER.
|
Academic Article
|
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.
|
Academic Article
|
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).
|
Academic Article
|
Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma.
|
Academic Article
|
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase 2 Trial.
|
Academic Article
|
Expression of the aV?3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro-tumorigenic activity in vivo through a GPI-anchored receptor, NgR2.
|